All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact

EHA2023 abstracts: What’s hot in MDS?

Jun 7, 2023

To help navigate the exciting content being presented at the European Hematology Association (EHA) 2023 Congress, the MDS Hub Steering Committee have provided their recommendations for the top abstracts to look out for in MDS.​

Friday, June 9






Oral presentation

Continuous tranfusion independence with imetelstat in heavily transfused non-del(5q) lower-risk myelodysplastic syndromes relapsed/refractory to erythropoiesis stimulating agents in IMERGE phase 3

Uwe Platzbecker


Oral presentation

Modulation of the immune landscape in lower-risk myelodysplastic syndromes with imetelstat-induced transfusion independency

Nicolas Chapuis


Poster presentation

Safety and efficacy of LP-108 as monotherapy and combined with azacitidine in patients with relapsed/refractory myelodysplastic syndromes, chronic myelomonocytic leukemia, or acute myeloid leukemia

Kristin Koenig


Poster presentation

Classification of MDS and AML based solely on genetics omitting blast counting – a way to resolve the discrepancies between classifications according to WHO and ICC?

Claudia Haferlach


Poster presentation

Updated substudy results for ivosidenib in IDH1-mutant relapsed/refractory myelodysplastic syndrome

Courtney DiNardo


Poster presentation

Analysis of patient-reported fatigue in IMERGE Ph3 trial of imetelstat vs placebo in heavily transfused non-del(5q) lower-risk myelodysplastic syndromes R/R to erythropoiesis stimulating agents

Mikkael Sekeres


Poster presentation

Treatment patterns and outcomes among patients with lower-risk myelodysplastic syndromes receiving luspatercept in routine clinical practice in the United States

Sudipto Mukherjee


Poster presentation

Analysis of response rates and outcomes in erythroid-predominant myelodysplastic syndromes (MDS) treated with venetoclax-based regimens

Alexandre Bazinet


Poster presentation

Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: results of a randomized clinical trial comparing 2 fractionation schedules

Uday R. Popat


Poster presentation

Upfront allogeneic hematopoietic stem cell transplantation can provide survival benefit versus hypomethylating agent in myelodysplastic syndrome with increased blasts I (MDS-IBI)

Runzhi Ma

Saturday, June 10

EHA 2023 abstracts

To download this document, click below.

Download here

More about...


Subscribe to get the best content related to MDS delivered to your inbox